On March 10, 2025, Cyclacel Pharmaceuticals agreed to buy certain assets related to Plogosertib from its UK subsidiary in liquidation for £250,000, with terms for future sales of these assets outlined. The agreement also includes the assignment of patent rights for Plogosertib.